Pfizer stock heads into the open after a flat close
Published on 09/08/2026 at 06:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 7, 2026, Pfizer stock finished near USD 28.42 on the NYSE, marking an essentially flat move in recent trading after a modest recovery in prior sessions, according to market commentary data.IT BOLTWISE market overview That level left Pfizer trading at a discount to many large pharmaceutical peers as analysts continued to debate its earnings trajectory and valuation.The Globe and Mail analysis Today, investors weigh sector sentiment and upcoming macro data as they prepare for the next session in Pfizer stock.
September 7, 2026 in numbers
Pfizer Inc. (ISIN US7170811035, NYSE: PFE) last appeared in consolidated quote and commentary overviews at a price point of USD 28.42 on September 7, 2026, with the stock described as trading near the upper end of its recent short-term range.IT BOLTWISE market overview Market data in that cross-market report highlighted a market capitalization of about USD 161.98 billion at that price on September 7, 2026, underlining the scale of the company in the global pharmaceuticals sector.IT BOLTWISE market overview Analyst-focused coverage the same week noted that Pfizer shares had gained around 14 percent year to date while still trading at roughly 10 times estimated forward earnings, a multiple viewed as low relative to broader large-cap healthcare valuations.The Globe and Mail analysis In quantitative terms, that combination of a sub-30 USD share price and low earnings multiple positioned the stock as a value-tilted play within big pharma, even after the year-to-date advance.
Context from recent commentary also stressed that Pfizer’s latest reported quarter delivered adjusted earnings per share of USD 0.77 and revenue of USD 15.03 billion for the second quarter of 2026, figures discussed in an article dated September 6, 2026 and tied to management’s guidance corridor for the year.IT BOLTWISE market overview Those numbers, together with a management outlook calling for full-year 2026 EPS between USD 2.80 and USD 3.00, were cited as a key backdrop for the current trading band around USD 28, because they help anchor expectations for how much earnings power supports the equity value.IT BOLTWISE market overview A separate opinion piece published on September 7, 2026 argued that despite the roughly 14 percent year-to-date gain, Pfizer’s share price near USD 28.77 around midday on September 3, 2026 still implied upside over the next 12 months based on a target of USD 32.72 and reiterated a buy stance, reinforcing the view that the recent close left room for further appreciation if execution and guidance hold.24/7 Wall St. commentary
Outlook for today
Today, Pfizer stock trades ahead of the next US session without a company-specific earnings release due, so attention turns to how broader healthcare and equity market trends may shape sentiment toward large pharmaceutical names. Recent valuation-focused pieces have emphasized that the stock’s roughly 10 times forward earnings multiple leaves it sensitive to changes in interest rates and sector risk appetite, meaning macro data or central-bank messaging scheduled for the coming days can influence demand for defensive, dividend-paying healthcare shares.The Globe and Mail analysis In addition, the consolidation of Pfizer’s second-quarter results and guidance in investor models, as highlighted in recent market commentary, keeps the November 4, 2026 earnings date on the radar as a future catalyst, with today’s trading likely framed by expectations for whether the company can maintain or improve its 2026 outlook.IT BOLTWISE market overview
